Clinical trial / 2010
Acute ingestion of Hibiscus sabdariffa extract decreased plasma monocyte chemoattractant protein-1 in humans
Researchers examined the anti-inflammatory effects of an aqueous Hibiscus sabdariffa extract in cultured blood cells and in a human clinical trial. In humans, acute ingestion of a 10 g dose was well tolerated and significantly reduced plasma concentrations of monocyte chemoattractant protein-1. The treatment did not alter other inflammatory cytokines or elevate plasma antioxidant capacity.
- Study type
- Acute clinical trial and in vitro study
- Who was studied
- Human volunteers (sample size not stated)
- What was measured
- Plasma MCP-1 and cytokine concentrations
THE PAPER
The aqueous extract of Hibiscus sabdariffa calices modulates the production of monocyte chemoattractant protein-1 in humans.
Beltrán-Debón R, Alonso-Villaverde C, Aragonès G, Rodríguez-Medina I, Rull A, Micol V, Segura-Carretero A, Fernández-Gutiérrez A, Camps J, Joven J. Phytomedicine, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.